A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization
A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization
Modern commercial data helps organizations find new patients and HCPs
現代商業數據幫助組織找到新的患者和醫療保健專業人員
PLEASANTON, Calif., Dec. 12, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced increasing momentum for Veeva Compass Patient, an emerging leader for anonymous patient longitudinal data. With unlimited data access, daily data, and the most complete data network supporting both retail and specialty brands, Compass Patient helps commercial teams at biopharmas of all sizes better support key use cases like patient journey, market sizing, and field force activation.
加利福尼亞州普萊森頓,2024年12月12日 /PRNewswire/ -- Veeva Systems(紐交所代碼:VEEV)今天宣佈Veeva Compass Patient的增長勢頭,成爲匿名患者縱向數據的新興領導者。憑藉無限的數據訪問、每日數據以及最完整的數據網絡,支持零售和專業品牌,Compass Patient幫助生物製藥公司更好地支持關鍵用例,如患者旅程、市場規模和現場團隊激活。
"We are using Veeva Compass Patient for many of our brands as it helps us find more HCPs and patients than traditional sources," said Sridutta Rao, executive director of commercial data and analytics solutions at Bayer. "Having unlimited access to a complete and modern dataset to generate insights for both retail prescriptions and in-office treatments gives us a better understanding of the entire patient journey."
「我們在許多品牌中使用Veeva Compass Patient,因爲它比傳統來源更能幫助我們找到更多的醫療保健專業人員和患者,」拜耳公司商業數據和分析解決方案的執行董事Sridutta Rao說。「擁有無限訪問完整和現代數據集的能力,爲零售處方和門診治療生成洞察,使我們更好地理解整個患者旅程。」
Compass Patient is licensed for use at the brand level and includes unlimited data access to all patient data. The Compass data network includes more than 300 million patients in the U.S., over three million healthcare providers and clinicians, 80+ billion prescription and medical records, and more than seven years of patient history.
Compass Patient被授權在品牌層面使用,包括對所有患者數據的無限訪問。Compass數據網絡包括美國超過30000萬名患者、超過300萬名醫療保健提供者和臨床醫生、80多億份處方和醫療記錄,以及超過七年的患者歷史。
"Veeva Compass Patient is the next generation of patient data for life sciences," said Peter Stark, executive vice president and general manager of Veeva Compass. "I'm excited to see our customer community growing and driving so much value through our partnership."
「Veeva Compass Patient是生命科學領域患者數據的下一代,」Veeva Compass的執行副總裁兼總經理Peter Stark說。「我很高興看到我們的客戶社區在不斷壯大,並通過我們的合作伙伴關係創造瞭如此多的價值。」
Veeva Compass Suite includes Veeva Compass Prescriber, projected prescriptions and procedures at the HCP, HCO, and ZIP level for retail and non-retail products, and Veeva Compass National, projected prescriptions and procedures at the state and national level for retail and non-retail products. Veeva Compass is part of Veeva Data Cloud, the modern, connected data platform for life sciences, which includes Veeva OpenData and Veeva Link.
Veeva Compass套件包括Veeva Compass Prescriber,按醫療保健專業人員、醫療保健組織和郵政編碼級別預計的處方和程序,零售和非零售產品,以及Veeva Compass National,按州和國家級別預計的處方和程序,零售和非零售產品。Veeva Compass是Veeva Data Cloud的一部分,這是一種現代、連接的數據平台,適用於生命科學,包括Veeva OpenData和Veeva Link。
Additional Information
For more on Veeva Compass, visit: veeva.com/Compass
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
附加信息
有關Veeva Compass的更多信息,請訪問:veeva.com/Compass
在LinkedIn上與Veeva聯繫:linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Systems Inc.
Veeva是全球生命科學行業的雲軟件領導者。Veeva致力於創新、產品卓越和客戶成功,服務超過1,000個客戶,從全球最大的生物製藥公司到新興生物技術公司。作爲一家公共利益公司,Veeva致力於平衡所有利益相關者的利益,包括客戶、員工、股東和其服務的行業。有關更多信息,請訪問veeva.com。
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Veeva的前瞻性聲明
本發佈包含有關Veeva產品和服務的前瞻性陳述,以及使用我們產品和服務所預期的結果或收益。這些陳述基於我們當前的預期。實際結果可能與本發佈中提供的結果有顯著差異,我們沒有義務更新這些陳述。有許多風險可能對我們的結果產生負面影響,包括在我們截至2024年10月31日的10-Q表格中的風險和不確定性披露,您可以在此找到(可能影響我們業務的風險總結見第36和37頁),以及在我們隨後向SEC提交的文件中,您可以在sec.gov訪問。
Contact:
Alison Borris
Veeva Systems
925-226-8821
[email protected]
聯繫:
艾莉森·博里斯
veeva systems
925-226-8821
[email protected]
SOURCE Veeva Systems
來源於veeva systems
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?
譯文內容由第三人軟體翻譯。